hasemtiger.blogg.se - Stryker icad

Stryker icad full#
Stryker icad trial#

OxiWear raises $1.While many medical device companies are seeing operating room doors shut in the face of their sales reps as hospitals strive to minimize contact during the pandemic, in this week’s DeviceTalks Weekly podcast, Spencer Stiles, group president of Stryker’s orthopaedic and spine groups, said surgeons are telling the ortho giant quite the opposite - that its medical device sales reps must be in the room.

FDA clears Avinger’s Pantheris for in-stent restenosis.

How medtech fared in the first waves of the pandemic.

Diabeloop, Terumo partner to bring automated insulin delivery to Europe.

FDA grants breakthrough nod to Blackrock Neurotech’s brain-computer interface.

FDA gives Bexson pre-IND guidance for ketamine formulation delivered by wearable pump.

Baxter bolsters fill-finish capabilities with $100M investment in Germany.

5 startups chosen for Boston Scientific-sponsored gBETA Medtech Black Founder Accelerator program.

The best places to work for medtech sales reps in 2022.

Convatec warns on some Avelle negative pressure wound therapy pumps.

Olympus announces $50M medtech venture capital fund.

Better Therapeutics completes enrollment in type 2 diabetes study.

Datar Cancer Genetics wins FDA breakthrough nod for breast cancer detection blood test.

ICU Medical’s Smiths Medical acquisition remains on track.

FDA says cardiac perforation problems appear more severe with Medtronic’s Micra.

BioMarin wins FDA approval for injection to increase growth in children with dwarfism.

FDA grants breakthrough device designation for Theradaptive’s spinal fusion implant.

Stryker icad full#

The unprecedented low complication rate shows that endovascular treatment may play an important role in optimizing clinical outcomes for patients suffering from this highly complex disease,” Stryker neurovascular division prez Mark Paul said in a press release.Įarlier this month, Stryker saw shares fall slightly despite announcing preliminary fourth quarter and full year 2017 sales results that met quarterly and yearly sales expectations.įiled Under: Clinical Trials, Stents, Vascular Tagged With: Stryker

Stryker icad trial#

“The Weave Trial results are a great step forward for the treatment of intracranial atherosclerotic disease. Using approved stents in the brain arteries may give new hope to patients suffering from stroke due to blockages from cholesterol plaque,” principal investigator Dr. Michael Alexander of Los Angeles’ Cedars-Sinai Neurovascular Center said in a prepared statement. “These trial results have the potential to change how stroke patients are treated in the future. Trial investigators said that results from the trial could lead to a shift in how physicians approach patient selection for endovascular therapy to treat ICAD. The 4% rate was significant when compared to the trials null hypothesis with high predictive probability rate that the true rate was 9.7%, the company said. Results from the FDA-mandated trial indicated that patients receiving treatment with the Wingspan stent system had a 2.6% rate of stroke or death, lower than the 4% pre-specified rate for early success. The Weave trial is a multi-center, prospective, post-market surveillance study which aimed to evaluate rates of stroke or death within 72 hours in patients treated with the Wingspan stent system. Stryker (NYSE: SYK) today released results from the post-market Weave trial of its Wingspan stent system designed for treating intracranial atherosclerotic disease.ĭata from the study was presented at the International Stroke Conference, the Kalamazoo, Mich.-based company said.